BIOLASE To Present At H.C. Wainwright's 22nd Annual Global Investor Conference

Rhea-AI Summary

BIOLASE, a leader in dental lasers, announced a presentation by Todd Norbe, President and CEO, and John Beaver, COO and CFO, at the H.C. Wainwright 22^nd Annual Global Investor Conference on September 16, 2020, at 11:00 AM PT. The presentation will cover the company’s recent progress and achievements and will include virtual one-on-one meetings with institutional investors. The live webcast can be accessed at this link or on BIOLASE's investor relations website, showcasing their innovative dental technology.

FOOTHILL RANCH, Calif., Sept. 11, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that Todd Norbe, President and Chief Executive Officer and John Beaver, Chief Operating Officer and Chief Financial Officer, will be providing an overview of the Company, as well as recent progress and achievements at the H.C. Wainwright 22^nd Annual Global Investor Conference on Wednesday, September 16, 2020 at 11:00 am Pacific Time (2:00 pm ET). 

The conference will feature virtual one-on-one meetings with the BIOLASE' executives and institutional investors are invited to request meeting times at tkehrli@evcgroup.com or through their H.C. Wainwright representative.  The formal presentation will be webcast live and will be available for replay at https://wsw.com/webcast/hcw7/biol/1595926 or in the investor relations section of BIOLASE's website at www.biolase.com.

About BIOLASE, Inc.

BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.  BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals.  BIOLASE's proprietary laser products incorporate approximately 261 patented and 52 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times.  BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients.  BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications.  BIOLASE has sold over 41,200 laser systems to date in over 80 countries around the world.  Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

View original content to download multimedia:http://www.prnewswire.com/news-releases/biolase-to-present-at-hc-wainwrights-22nd-annual-global-investor-conference-301128435.html

SOURCE BIOLASE, Inc.

FAQ

What is the date and time of BIOLASE's presentation at the H.C. Wainwright Investor Conference?

BIOLASE's presentation is scheduled for September 16, 2020, at 11:00 AM Pacific Time.

Who will present on behalf of BIOLASE at the conference?

Todd Norbe, President and CEO, and John Beaver, COO and CFO, will present for BIOLASE.

How can investors access BIOLASE's presentation?

Investors can access the live webcast of BIOLASE's presentation at this link.

What is the focus of BIOLASE's presentation at the conference?

The presentation will focus on BIOLASE's recent progress and achievements in dental lasers.

How can institutional investors schedule meetings with BIOLASE executives during the conference?

Institutional investors can request meetings via email at tkehrli@evcgroup.com or through their H.C. Wainwright representative.